Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: Specificity and relation with rheumatoid factor

Anti-citrullinated protein/peptide antibodies (ACPA) are highly specific and sensitive markers for rheumatoid arthritis (RA). For instance, for the anti-CCP2 assay, sensitivities ranging from 55% to 80% and specificities ranging from 90% to 98% have been reported. Despite their high specificity, rec...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity reviews 2005-09, Vol.4 (7), p.468-474
Main Authors: Vander Cruyssen, B., Peene, I., Cantaert, T., Hoffman, I.E.A., De Rycke, L., Veys, E.M., De Keyser, F.
Format: Article
Language:English
Subjects:
Animals
Anti-citrullinated peptide/protein antibodies (ACPA)
Antibody Specificity
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - metabolism
Biomarkers - metabolism
Citrulline - immunology
Citrulline - metabolism
Humans
Peptides - immunology
Peptides - metabolism
Peptides, Cyclic - immunology
Peptides, Cyclic - metabolism
Rheumatoid arthritis
Rheumatoid factor
Rheumatoid Factor - physiology
Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-citrullinated protein/peptide antibodies (ACPA) are highly specific and sensitive markers for rheumatoid arthritis (RA). For instance, for the anti-CCP2 assay, sensitivities ranging from 55% to 80% and specificities ranging from 90% to 98% have been reported. Despite their high specificity, recent reports have suggested that ACPA may be found in some patients with other rheumatic autoimmune diseases, including psoriatic arthritis, systemic lupus erythematosus and Sjögren's syndrome. Also, the differences between the classical rheumatoid factor (RF) and ACPA, as well as the complementarity between both tests have recently been demonstrated more clearly. Indeed, both antibody systems have a different association with specific RA features like extra-articular manifestations, a different association with the HLA shared epitope and, behave differently following anti-TNF therapy.
ISSN:1568-9972
1568-9972
DOI:10.1016/j.autrev.2005.04.018